Clearmind Medicine
CMND
8 hedge funds and large institutions have $5.49M invested in Clearmind Medicine in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
1,891% more capital invested
Capital invested by funds: $276K → $5.49M (+$5.22M)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 → 8 (+4)
0.03% more ownership
Funds ownership: 0.01% → 0.04% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
+$483K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$201K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$59.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25K |
| 5 |
HF
HRT Financial
New York
|
+$18.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$27.9K |
CMND Hedge Fund Activity: Q3 2024 in Review
8 institutional investors reported a position in Clearmind Medicine (CMND) for Q3 2024, worth a combined $5.49M — up 1,891% from $276K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CMND positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Gotham Asset Management, opening a new position worth an estimated $483K. The largest seller was Geode Capital Management, exiting entirely with an estimated $27.9K sold.
- 8 institutional investors held Clearmind Medicine (CMND) as of Q3 2024, up from 4 in Q2 2024.
- Funds reported $5.49M of Clearmind Medicine stock for Q3 2024, up 1,891% quarter-over-quarter.
- 5 funds opened new Clearmind Medicine positions in Q3 2024 and 1 closed out, a net change of +4 holders.
- The largest Clearmind Medicine buyer in Q3 2024 was Gotham Asset Management, an estimated $483K added.
- The largest Clearmind Medicine seller in Q3 2024 was Geode Capital Management, an estimated $27.9K sold.
Based on aggregated 13F filings for Q3 2024.